Genvor Incorporated (OTCPK: GNVR)
Health Care · Biotechnology · US
$0.55
+10.51% today · -38.9% 1Y
Genvor Incorporated (OTCPK: GNVR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.03M.
Over the last twelve months the share price has lost 38.9%, trading between 0.01 and 3.00.
Tweenvest scores Genvor Incorporated across four factors: quality 4/100. Its strongest factor is quality.
GNVR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.03M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 548,308.42
- 52-week high
- $3.00
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 36.41M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.